Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis.
PBS/IC
autoimmunity
interstitial cystitis
monoclonal antibody
Journal
Biologics : targets & therapy
ISSN: 1177-5475
Titre abrégé: Biologics
Pays: New Zealand
ID NLM: 101321511
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
02
2022
accepted:
06
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
An emerging theory regarding the potentially autoimmune nature of painful bladder syndrome/interstitial cystitis (PBS/IC) had led to several studies being conducted to assess the possible therapeutic effect of immunotherapeutic options for PBS/IC. This review presents the available evidence regarding the potential autoimmunity-based pathogenesis of PBS/IC and focuses on a main representative of the immunotherapeutic modalities for PBS/IC, aiming to summarize, evaluate, and present available data regarding the potential therapeutic role of monoclonal antibodies for PBS/IC patients. A non-systematic narrative and interpretative literature review was performed. The monoclonal antibodies included in the review were the anti-tumor necrosis factor-α (anti-TNF-α) agents adalimumab, which showed no difference compared to placebo, and certolizumab pegol, which showed statistically important differences in all outcome measures compared to placebo at the 18-week follow-up visit. Anti-nerve growth factor (anti-NGF) agents were also reviewed, including tanezumab, which showed both positive and negative efficacy results compared to placebo, and fulranumab, the study of which was discontinued owing to adverse events. In summary, monoclonal antibody therapy remains to be further researched in order for it to be proposed as a promising future treatment option for PBS/IC.
Identifiants
pubmed: 35619987
doi: 10.2147/BTT.S290286
pii: 290286
pmc: PMC9129098
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
47-55Informations de copyright
© 2022 Mykoniatis et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
N Engl J Med. 2007 Jul 19;357(3):239-50
pubmed: 17634459
Urology. 1999 Sep;54(3):450-3
pubmed: 10475352
J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1211-20
pubmed: 10856157
J Urol. 1994 Sep;152(3):869-73
pubmed: 8051739
Inflamm Bowel Dis. 2007 Nov;13(11):1323-32
pubmed: 17636564
Arthritis Rheum. 2004 Nov;50(11):3637-45
pubmed: 15529387
Pain. 2003 Oct;105(3):489-497
pubmed: 14527709
J Urol. 2005 Feb;173(2):630-4
pubmed: 15643278
Int J Clin Pract. 2016 Jun;70(6):493-505
pubmed: 27238963
Int Urogynecol J. 2019 Nov;30(11):1795-1805
pubmed: 31073635
BioDrugs. 2008;22(5):331-7
pubmed: 18778114
Urology. 2011 Feb;77(2):313-9
pubmed: 21295246
Int J Urol. 2014 Aug;21(8):805-9
pubmed: 24724573
Ther Adv Musculoskelet Dis. 2022 Jan 19;14:1759720X211067639
pubmed: 35069811
Urology. 2002 Nov;60(5):742-8
pubmed: 12429288
Int Neurourol J. 2021 Jun;25(2):99-110
pubmed: 34218637
J Urol. 1997 Mar;157(3):1083-7
pubmed: 9072548
Neuroscience. 1997 May;78(2):449-59
pubmed: 9145801
J Urol. 2007 Mar;177(3):1186-90
pubmed: 17296442
Am J Physiol Renal Physiol. 2021 Feb 1;320(2):F174-F182
pubmed: 33308017
Ann Rheum Dis. 2009 Jun;68(6):805-11
pubmed: 19015206
Protein Sci. 2008 Aug;17(8):1326-35
pubmed: 18505735
Urology. 2012 Nov;80(5):1105-10
pubmed: 23010344
Expert Opin Biol Ther. 2017 Dec;17(12):1471-1480
pubmed: 28874100
Int Urogynecol J. 2021 May;32(5):1061-1071
pubmed: 32886173
Ann Rheum Dis. 2015 Jun;74(6):1202-11
pubmed: 24625625
J Pain Res. 2016 Jun 08;9:373-83
pubmed: 27354823
J Urol. 2003 Sep;170(3):810-5
pubmed: 12913705
J Urol. 2002 Aug;168(2):819-25
pubmed: 12131374
J Manag Care Spec Pharm. 2017 Apr;23(4):474-482
pubmed: 28345436
Pain. 2011 Oct;152(10):2248-2258
pubmed: 21696889
J Urol. 2010 May;183(5):1853-8
pubmed: 20303115
Br J Urol. 1994 May;73(5):508-15
pubmed: 8012772
Front Med (Lausanne). 2021 Sep 20;8:747098
pubmed: 34616760
J Urol. 2008 Feb;179(2):552-5
pubmed: 18082224
BJU Int. 2018 Nov;122(5):729-743
pubmed: 29777618
BMC Urol. 2017 Jan 5;17(1):2
pubmed: 28056917
J Chin Med Assoc. 2018 Mar;81(3):248-254
pubmed: 29223727
Urology. 2007 Apr;69(4 Suppl):34-40
pubmed: 17462477
Mod Rheumatol. 2014 Sep;24(5):725-33
pubmed: 24372225
Trends Pharmacol Sci. 2006 Feb;27(2):85-91
pubmed: 16376998
Pain. 2013 Oct;154(10):1910-1919
pubmed: 23748114
Neurology. 2014 Aug 12;83(7):628-37
pubmed: 25008392
J Urol. 2011 May;185(5):1716-21
pubmed: 21420111
Eur Urol Focus. 2021 Jul;7(4):877-885
pubmed: 32127327
J Clin Invest. 1991 Nov;88(5):1709-15
pubmed: 1939656
J Urol. 2014 Jan;191(1):77-82
pubmed: 23792149
PLoS One. 2013 Oct 17;8(10):e76779
pubmed: 24146927
Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R534-47
pubmed: 20032263
Eur Urol. 2018 Nov;74(5):623-630
pubmed: 30072210
J Pain. 2012 Aug;13(8):790-8
pubmed: 22784777
Int Urogynecol J. 2013 Dec;24(12):2049-57
pubmed: 23670165
Life Sci. 1999;64(6-7):419-28
pubmed: 10069505
N Engl J Med. 2010 Oct 14;363(16):1521-31
pubmed: 20942668
PLoS One. 2021 Sep 7;16(9):e0256800
pubmed: 34492065
Urology. 2001 Jun;57(6 Suppl 1):47-55
pubmed: 11378050
BJU Int. 2000 May;85(8):995-9
pubmed: 10792194
RMD Open. 2015 Jun 25;1(1):e000119
pubmed: 26509074
Br J Urol. 1989 Jan;63(1):58-63
pubmed: 2920261
J Urol. 1994 Aug;152(2 Pt 1):355-61
pubmed: 8015071
Cochrane Database Syst Rev. 2020 Jul 30;7:CD013325
pubmed: 32734597
J Urol. 2016 Apr;195(4 Pt 1):942-8
pubmed: 26576710
Int Urogynecol J. 2021 May;32(5):1129-1141
pubmed: 33638677
BJU Int. 2010 Dec;106(11):1681-5
pubmed: 19751258